Image

Global Acute Intermittent Porphyria Market – Industry Trends and Forecast to 2029

  • Healthcare
  • Upcoming Report
  • Feb 2022
  • Global
  • 350 Pages
  • No of Tables: 60
  • No of Figures: 220
  • Healthcare
  • Upcoming Report
  • Feb 2022
  • Global
  • 350 Pages
  • No of Tables: 60
  • No of Figures: 220

Global Acute Intermittent Porphyria Market, By Diagnosis (Blood Test, Urine Test, DNA Test, Serum Test), Treatment (Gonadotropin-Releasing Hormone Analogues, Prophylactic Hematin Infusions), End Users (Hospitals, Clinics, Research Centers), Country (U.S., Canada, Mexico, Germany, Italy, U.K., France, Spain, Netherland, Belgium, Switzerland, Turkey, Russia, Rest of Europe, Japan, China, India, South Korea, Australia, Singapore, Malaysia, Thailand, Indonesia, Philippines, Rest of Asia- Pacific, Brazil, Argentina, Rest of South America, South Africa, Saudi Arabia, UAE, Egypt, Israel, Rest of Middle East and Africa) Industry Trends and Forecast to 2029

Acute Intermittent Porphyria Market

Market Analysis and Insights Global Acute Intermittent Porphyria Market

Data Bridge Market Research analyses that the acute intermittent porphyria market is growing at a CAGR of 5.9% in the forecast period of 2022-2029.

Acute intermittent porphyria (AIP) is a rare upset that's characterised by partial deficiency of the catalyst hydroxymethylbilane synthase (also referred to as porphobilinogen deaminase). This catalyst deficiency is end up within the accumulation of pigment precursors within the body..

The rising incidences of the metabolic disorders is the major factor accelerating the growth of the acute intermittent porphyria market. Furthermore, gastrointestinal issues and urinary tract issues, rapidly expanding growth in biotechnology and pharmaceutical speculation for research and development are also expected to drive the growth of the acute intermittent porphyria market. However, increase in treatment cost coupled with advancing health care technologies restrains the acute intermittent porphyria market, whereas, poor reimbursement facilities in the developing regions challenge market growth.

In addition, increase in availability of funds and rapidly increasing government support for research & development will create ample opportunities for the acute intermittent porphyria market.

This acute intermittent porphyria market report provides details of new recent developments, trade regulations, import export analysis, production analysis, value chain optimization, market share, impact of domestic and localised market players, analyses opportunities in terms of emerging revenue pockets, changes in market regulations, strategic market growth analysis, market size, category market growths, application niches and dominance, product approvals, product launches, geographic expansions, technological innovations in the market. To gain more info on acute intermittent porphyria market contact Data Bridge Market Research for an Analyst Brief, our team will help you take an informed market decision to achieve market growth.

Global Acute Intermittent Porphyria Market Scope and Market Size

The acute intermittent porphyria market is segmented on the type of diagnosis, treatment and end users. The growth amongst these segments will help you analyse meagre growth segments in the industries, and provide the users with valuable market overview and market insights to help them in making strategic decisions for identification of core market applications.

  • On the basis of diagnosis, the acute intermittent porphyria market is segmented into blood test, urine test, DNA test, and serum test.
  • On the basis of treatment, the acute intermittent porphyria market is segmented into gonadotropin-releasing hormone analogues, and prophylactic hematin infusions.
  • Based on end users, the acute intermittent porphyria market is divided into hospital, clinics, and research centers.

Acute Intermittent Porphyria Market Country Level Analysis

The acute intermittent porphyria market is analysed and market size insights and trends are provided by country, diagnosis, treatment and end users as referenced above.

The countries covered in the acute intermittent porphyria market report are U.S., Canada and Mexico in North America, Germany, France, U.K., Netherlands, Switzerland, Belgium, Russia, Italy, Spain, Turkey, Rest of Europe in Europe, China, Japan, India, South Korea, Singapore, Malaysia, Australia, Thailand, Indonesia, Philippines, Rest of Asia-Pacific (APAC) in the Asia-Pacific (APAC), Saudi Arabia, U.A.E, South Africa, Egypt, Israel, Rest of Middle East and Africa (MEA) as a part of Middle East and Africa (MEA), Brazil, Argentina and Rest of South America as part of South America.

North America dominates the acute intermittent porphyria market in terms of market share and market revenue and will continue to flourish its dominance during the forecast period. This is owing to the well-developed technology, rising patient with genetic metabolic disorders along with increased healthcare spending and rising government support for R&D in this particular region. Asia-Pacific on the other hand is projected to exhibit the highest growth rate during the forecast period owing to the strong presence of rapidly developing healthcare technology, and rise in patient population base and rising healthcare expenditure in the region.

The country section of the acute intermittent porphyria market report also provides individual market impacting factors and changes in regulation in the market domestically that impacts the current and future trends of the market. Data points such as consumption volumes, production sites and volumes, import export analysis, price trend analysis, cost of raw materials, down-stream and upstream value chain analysis are some of the major pointers used to forecast the market scenario for individual countries. Also, presence and availability of global brands and their challenges faced due to large or scarce competition from local and domestic brands, impact of domestic tariffs and trade routes are considered while providing forecast analysis of the country data.

Healthcare Infrastructure Growth Installed Base and New Technology Penetration

The acute intermittent porphyria market also provides you with detailed market analysis for every country growth in healthcare expenditure for capital equipment, installed base of different kind of products for acute intermittent porphyria market, impact of technology using life line curves and changes in healthcare regulatory scenarios and their impact on the acute intermittent porphyria market. The data is available for historic period 2010 to 2020.

Competitive Landscape and Acute Intermittent Porphyria Market Share Analysis

The acute intermittent porphyria market competitive landscape provides details by competitor. Details included are company overview, company financials, revenue generated, market potential, investment in research and development, new market initiatives, global presence, production sites and facilities, production capacities, company strengths and weaknesses, product launch, product width and breadth, application dominance. The above data points provided are only related to the companies’ focus related to acute intermittent porphyria market.

Some of the major players operating in the acute intermittent porphyria market report are Boston Scientific Corporation, Koninklijke Philips N.V., Siemens, Dahaner, F. Hoffmann-La Roche Ltd, Bio-Rad Laboratories, Inc., Siemens AG, ARKRAY, Inc., Sysmex Corporation, ACON Laboratories, Inc., Nurotron Biotechnology Co. Ltd., Sonova, C.R. Bard Inc., and 3M among other


SKU-

Why Choose Us


Frequently Asked Questions

By 2029, the Acute Intermittent Porphyria Market will witness a raise of 5.9% in the CAGR value.
The segmentations covered in the Acute Intermittent Porphyria Market report are the type of diagnosis, treatment, and end users.
The major players focused in the Acute Intermittent Porphyria Market are Boston Scientific Corporation, Koninklijke Philips N.V., Siemens, Dahaner, F. Hoffmann-La Roche Ltd, Bio-Rad Laboratories, Inc., Siemens AG, ARKRAY, Inc., Sysmex Corporation, ACON Laboratories, Inc., Nurotron Biotechnology Co. Ltd., Sonova, C.R. Bard Inc., and 3M among other
In terms of both revenue and market share, North America now dominates the Acute Intermittent Porphyria Market, and this trend is expected to continue. This is because of the region's advanced technology, growing numbers of people with hereditary metabolic diseases, rising healthcare costs, and increasing government funding for R&D.